Skip to main content

Biomarkers and Correlative Endpoints for Immunotherapy Trials: What Can We Learn in Lung Cancer from Other Tumor Types?

Publication ,  Journal Article
Morse, MA; Osada, T; Hobeika, A; Patel, S; Lyerly, HK
Published in: American Society of Clinical Oncology Educational Book
May 2013

Immunotherapies for lung cancer are reaching phase III clinical trial, but the ultimate success likely will depend on developing biomarkers to guide development and choosing patient populations most likely to benefit. Because the immune response to cancer involves multiple cell types and cytokines, some spatially and temporally separated, it is likely that multiple biomarkers will be required to fully characterize efficacy of the vaccine and predict eventual benefit. Peripheral blood markers of response, such as the ELISPOT assay and cytokine flow cytometry analyses of peripheral blood mononuclear cells following immunotherapy, remain the standard approach, but it is increasingly important to obtain tissue to study the immune response at the site of the tumor. Earlier clinical endpoints such as response rate and progression-free survival do not correlate with overall survival demonstrated for some immunotherapies, suggesting the need to develop other intermediary clinical endpoints. Insofar as all these biomarkers and surrogate endpoints are relevant in multiple malignancies, it may be possible to extrapolate findings to immunotherapy of lung cancer.

Duke Scholars

Published In

American Society of Clinical Oncology Educational Book

DOI

EISSN

1548-8756

ISSN

1548-8748

Publication Date

May 2013

Issue

33

Start / End Page

e287 / e293

Publisher

American Society of Clinical Oncology (ASCO)
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Morse, M. A., Osada, T., Hobeika, A., Patel, S., & Lyerly, H. K. (2013). Biomarkers and Correlative Endpoints for Immunotherapy Trials: What Can We Learn in Lung Cancer from Other Tumor Types? American Society of Clinical Oncology Educational Book, (33), e287–e293. https://doi.org/10.14694/edbook_am.2013.33.e287
Morse, Michael A., Takuya Osada, Amy Hobeika, Sandip Patel, and H Kim Lyerly. “Biomarkers and Correlative Endpoints for Immunotherapy Trials: What Can We Learn in Lung Cancer from Other Tumor Types?American Society of Clinical Oncology Educational Book, no. 33 (May 2013): e287–93. https://doi.org/10.14694/edbook_am.2013.33.e287.
Morse MA, Osada T, Hobeika A, Patel S, Lyerly HK. Biomarkers and Correlative Endpoints for Immunotherapy Trials: What Can We Learn in Lung Cancer from Other Tumor Types? American Society of Clinical Oncology Educational Book. 2013 May;(33):e287–93.
Morse, Michael A., et al. “Biomarkers and Correlative Endpoints for Immunotherapy Trials: What Can We Learn in Lung Cancer from Other Tumor Types?American Society of Clinical Oncology Educational Book, no. 33, American Society of Clinical Oncology (ASCO), May 2013, pp. e287–93. Crossref, doi:10.14694/edbook_am.2013.33.e287.
Morse MA, Osada T, Hobeika A, Patel S, Lyerly HK. Biomarkers and Correlative Endpoints for Immunotherapy Trials: What Can We Learn in Lung Cancer from Other Tumor Types? American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology (ASCO); 2013 May;(33):e287–e293.

Published In

American Society of Clinical Oncology Educational Book

DOI

EISSN

1548-8756

ISSN

1548-8748

Publication Date

May 2013

Issue

33

Start / End Page

e287 / e293

Publisher

American Society of Clinical Oncology (ASCO)